{"version":"1.0","provider_name":"Kompetenz statt Demenz","provider_url":"https:\/\/kompetenz-statt-demenz.dsgip.de\/en\/","author_name":"Jens Br\u00fcnnler","author_url":"https:\/\/kompetenz-statt-demenz.dsgip.de\/en\/author\/j-bruennler\/","title":"New trails on anti-Amyloid drug failed &#8211; Kompetenz statt Demenz","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Lj6S89Lso1\"><a href=\"https:\/\/kompetenz-statt-demenz.dsgip.de\/en\/anti-amyloid-drug-failed\/\">New trails on anti-Amyloid drug failed<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kompetenz-statt-demenz.dsgip.de\/en\/anti-amyloid-drug-failed\/embed\/#?secret=Lj6S89Lso1\" width=\"600\" height=\"338\" title=\"&#8220;New trails on anti-Amyloid drug failed&#8221; &#8212; Kompetenz statt Demenz\" data-secret=\"Lj6S89Lso1\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/kompetenz-statt-demenz.dsgip.de\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/kompetenz-statt-demenz.dsgip.de\/wp-content\/uploads\/2019\/12\/microscope-1817641_1920.jpg","thumbnail_width":1920,"thumbnail_height":1280,"description":"Lanabecestat is a potent inhibitor of Amyloid beta (A\u03b2) formation \u2013 the main component of amyloid plaques. A\u03b2 is formed through cleavage of amyloid precursor protein (APP) by proteases known as secretases (\u03b2 and \u03b3). The Beta-site-APP-cleaving enzyme 1 (BACE1) cleaves APP at the \u03b2-secretase site, after which APP is cleaved by \u03b3 secretase to generate A\u03b2 peptides. Lanabecestat inhibits BACE1 and was able to reduce levels of A\u03b21-40 and A\u03b21-42 in the brain, cerebrospinal fluid (CSF), and plasma in several animal models, as well as in human CSF and plasma. Besides that, Lanabecestat is brain permeable meaning that an adequate amount of this substance is able to reach the brain after oral intake."}